AD182

AD182 is an investigational **oral fixed-dose combination** of atomoxetine and lemborexant developed by Apnimed for obstructive sleep apnea. Atomoxetine inhibits the norepinephrine transporter, increasing noradrenergic signaling that may improve upper-airway dilator-muscle activity during sleep. Lemborexant is a dual orexin receptor antagonist intended to reduce wake-promoting orexin signaling and support sleep continuity. AD182 was evaluated as a single bedtime dose in Apnimed's completed Phase 2 APX-001 randomized, double-blind, placebo-controlled crossover study in adults with obstructive sleep apnea; the program showed a trend toward reduced sleep-apnea-specific hypoxic burden versus placebo.

Other names

Ato-Lemboatomoxetine + lemborexant